DOI: 10.36347/sasjm.2016.v02i02.002

Pages: Page: 29-34

The aim of the study is to determine serum mesothelin level in patients with endometrial cancer and its level in different histopathological subtypes. The ultimate goal is to know if we can set serum mesothelin as a marker for endometrial cancer. The method was serum samples were collected from 45women as cases attending the gynecological oncology clinic at El Shatby Maternity University Hospital, after their diagnosing as endometrial cancer. And another serum samples were collected from 45 women as a control group attending El-Shatby Maternity University Hospital for other therapeutic reasons after applying the exclusion and inclusion criteria. A sandwich ELISA tech.wes used to detect the level of mesothelin in the sera of cases and control groups. The results from the receiver operating characteristic (ROC) curve analysis, we found that mesothelin is a good indicator for diagnosis and anticipation of endometrial cancer. The best cut-off that maximizes (sensitivity + specificity) is 2.46 (ng/ml). At this level, the sensitivity is 75.56 and specificity is 86.67. In conclusion using a quantitative ELISA for serum mesothelin detection found to be elevated in 75.5% of endometrial cancer patients; these results have identified serum mesothelin a potential biomarker for these cancers. However studies involving much larger patients' samples are needed to fully characterize the sensitivity and specificity of the assay.